Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Publication year range
1.
Nature ; 571(7764): 284-288, 2019 07.
Article in English | MEDLINE | ID: mdl-31263273

ABSTRACT

Hedgehog signalling is fundamental to embryonic development and postnatal tissue regeneration1. Aberrant postnatal Hedgehog signalling leads to several malignancies, including basal cell carcinoma and paediatric medulloblastoma2. Hedgehog proteins bind to and inhibit the transmembrane cholesterol transporter Patched-1 (PTCH1), which permits activation of the seven-transmembrane transducer Smoothened (SMO) via a mechanism that is poorly understood. Here we report the crystal structure of active mouse SMO bound to both the agonist SAG21k and to an intracellular binding nanobody that stabilizes a physiologically relevant active state. Analogous to other G protein-coupled receptors, the activation of SMO is associated with subtle motions in the extracellular domain, and larger intracellular changes. In contrast to recent models3-5, a cholesterol molecule that is critical for SMO activation is bound deep within the seven-transmembrane pocket. We propose that the inactivation of PTCH1 by Hedgehog allows a transmembrane sterol to access this seven-transmembrane site (potentially through a hydrophobic tunnel), which drives the activation of SMO. These results-combined with signalling studies and molecular dynamics simulations-delineate the structural basis for PTCH1-SMO regulation, and suggest a strategy for overcoming clinical resistance to SMO inhibitors.


Subject(s)
Cell Membrane/chemistry , Hedgehog Proteins/agonists , Signal Transduction/drug effects , Smoothened Receptor/agonists , Smoothened Receptor/metabolism , Sterols/pharmacology , Animals , Binding Sites , Biosensing Techniques , Catalytic Domain/drug effects , Cell Membrane/metabolism , Cholesterol/chemistry , Cholesterol/metabolism , Cholesterol/pharmacology , Hedgehog Proteins/metabolism , Ligands , Mice , Models, Molecular , Molecular Dynamics Simulation , Patched-1 Receptor/antagonists & inhibitors , Patched-1 Receptor/metabolism , Protein Conformation , Protein Stability , Single-Chain Antibodies/immunology , Smoothened Receptor/antagonists & inhibitors , Smoothened Receptor/chemistry , Sterols/chemistry , Sterols/metabolism , Xenopus Proteins/chemistry
2.
J Dermatol ; 46(6): 507-514, 2019 Jun.
Article in English | MEDLINE | ID: mdl-31038235

ABSTRACT

Skin adnexal cancers (SAC) are a heterogeneous group of rare malignancies with histological differentiation towards epithelial adnexa, which lack effective systemic treatments. The aim of this work is to identify any potentially druggable genomic alterations for possible targeted therapies. Cases of primary or recurrent/metastatic (RM) SAC between 2002 and 2014 were identified by searching the institutional cancer registration database. Histological sections of all referral cases were reviewed by a dedicated pathologist to confirm diagnosis. Immunohistochemistry was performed to assess the expression of androgen receptors (AR) and human epidermal growth factor receptor type 2 (HER2). Targeted next-generation sequencing (T-NGS) was performed to identify targetable mutations (panel of 50 genes analyzed by Cancer Hotspot Panel, Ion-Torrent Personal Genome Machine). Mutational analysis of the PTCH1 gene not present in the T-NGS panel was assessed by Sanger sequencing. A total of 45 cases with available histological samples were identified (35 primary, 10 RM). The most frequent histological type was porocarcinoma (n = 12). Globally, 14 cases (31%) were AR+ (6/10 RM, 60%; 8/35 primary, 23%). HER2 was shown as 2+ in eight of 42 (19%) cases (2/9 RM, 22%; 6/33 primary, 18%). DNA was adequate for T-NGS analysis in 25 cases. In the majority of cases (17 cases, 68%) at least one mutation in oncogenes or tumor suppressor genes was found: the most frequent ones involved TP.53 (13 cases, 76% of mutated SAC) and PIK3CA (three cases, 18%). The rate of PTCH1 mutation was 30%. These findings support the use of molecular screening in patients with advanced SAC.


Subject(s)
Biomarkers, Tumor/genetics , Neoplasm Recurrence, Local/genetics , Neoplasms, Adnexal and Skin Appendage/genetics , Sebaceous Gland Neoplasms/genetics , Sweat Gland Neoplasms/genetics , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Biomarkers, Tumor/antagonists & inhibitors , Class I Phosphatidylinositol 3-Kinases/antagonists & inhibitors , Class I Phosphatidylinositol 3-Kinases/genetics , DNA Mutational Analysis , Female , High-Throughput Nucleotide Sequencing , Humans , Male , Molecular Targeted Therapy/methods , Mutation , Mutation Rate , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/prevention & control , Neoplasms, Adnexal and Skin Appendage/drug therapy , Neoplasms, Adnexal and Skin Appendage/pathology , Patched-1 Receptor/antagonists & inhibitors , Patched-1 Receptor/genetics , Receptor, ErbB-2/antagonists & inhibitors , Receptor, ErbB-2/genetics , Retrospective Studies , Sebaceous Gland Neoplasms/drug therapy , Sebaceous Gland Neoplasms/pathology , Sweat Gland Neoplasms/drug therapy , Sweat Gland Neoplasms/pathology , Tumor Suppressor Protein p53/antagonists & inhibitors , Tumor Suppressor Protein p53/genetics
3.
Cell Physiol Biochem ; 48(4): 1416-1432, 2018.
Article in English | MEDLINE | ID: mdl-30064125

ABSTRACT

BACKGROUND/AIMS: Adipocyte-derived exosomes (ADEs) stimulate the activation of macrophages and contribute to the development of insulin resistance. Sonic Hedgehog (Shh) is an exosome-carrying protein and stimulates macrophages to secrete inflammatory cytokines. However, the impact of ADEs carrying Shh on the pro-inflammatory activation of macrophages and consequently, adipocyte insulin resistance is unclear. METHODS: 3T3-L1 adipocytes were cultured with high glucose and insulin to imitate the pathogeny of insulin resistance. ADEs were isolated from conditioned media of 3T3-L1 adipocytes via differential ultracentrifugation. We explored the role of ADEs carrying Shh in the polarization of macrophages by flow cytometry. Western blot and electrophoretic mobility shift assay (EMSA) were performed to determine the activation of Shh-mediated signalling pathways. The effects of ADE-treated macrophages on adipocyte insulin signalling were studied by Western blot. RESULTS: We found that circulating Shh-positive exosomes were increased in type 2 diabetes patients. High glucose and insulin increased the secretion of Shh-positive ADEs. The ADEs carrying Shh induced pro-inflammatory or M1 polarization of bone marrow-derived macrophages (BMDM) and RAW 264.7 macrophages. Inhibitors of Ptch and PI3K blocked the M1 polarization induced by ADEs, which suggests that ADEs carrying Shh mediated M1 macrophage polarization through the Ptch/PI3K signalling pathway. ADE-treated RAW 264.7 macrophages were subsequently used to assess the effect on insulin signalling in adipocytes. Using a co-culture assay, we showed that both ADE-treated macrophages and exosomes from these macrophages could decrease the expression of insulin-resistant substrate-1 (IRS-1) and hormone-sensitive lipase (HSL) in adipocytes. Inhibitors of Ptch and PI3K blocked the down-regulation of IRS-1 and HSL induced by ADE-treated macrophages. CONCLUSION: Together, these data indicate that ADEs carrying Shh induce the M1 polarization of macrophages, which contributes to insulin resistance in adipocytes through the Ptch/PI3K pathway.


Subject(s)
Diabetes Mellitus, Type 2/pathology , Exosomes/metabolism , Hedgehog Proteins/metabolism , Patched-1 Receptor/metabolism , Phosphatidylinositol 3-Kinases/metabolism , 3T3-L1 Cells , Adipocytes/cytology , Adipocytes/metabolism , Animals , Diabetes Mellitus, Type 2/metabolism , Hedgehog Proteins/antagonists & inhibitors , Hedgehog Proteins/genetics , Humans , Insulin Receptor Substrate Proteins/metabolism , Insulin Resistance , Macrophages/cytology , Macrophages/immunology , Macrophages/metabolism , Male , Mice , Mice, Inbred C57BL , Middle Aged , Patched-1 Receptor/antagonists & inhibitors , RAW 264.7 Cells , RNA Interference , RNA, Small Interfering/metabolism , Signal Transduction
4.
Exp Mol Med ; 49(12): e412, 2017 12 15.
Article in English | MEDLINE | ID: mdl-29244790

ABSTRACT

This study aimed to investigate the effect of Patched-1 (PTC1) and PTC2 silencing in a rat model, on Hedgehog (Hh) pathway-mediated recovery from spinal cord injury (SCI). An analytical emphasis on the relationship between the sonic hedgehog (Shh) pathway and nerve regeneration was explored. A total of 126 rats were divided into normal, sham, SCI, negative control (NC), PTC1-RNAi, PTC2-RNAi and PTC1/PTC2-RNAi groups. The Basso, Beattie and Bresnahan (BBB) scale was employed to assess hind limb motor function. Quantitative real-time polymerase chain reaction and western blotting were performed to examine the mRNA and protein levels of PTC1, PTC2, Shh, glioma-associated oncogene homolog 1 (Gli-1), Smo and Nestin. Tissue morphology was analyzed using immunohistochemistry, and immunofluorescent staining was conducted to detect neurofilament protein 200 (NF-200) and glial fibrillary acidic protein (GFAP). The PTC1/PTC2-RNAi group displayed higher BBB scores than the SCI and NC groups. Shh, Gli-1, Smo and Nestin expression levels were elevated in the PTC1/PTC2-RNAi group. PTC1 and PTC2 mRNA and protein expression was lower in the PTC1/PTC2-RNAi group than in the normal, sham and SCI groups. Among the seven groups, the PTC1/PTC2-RNAi group had the largest positive area of NF-200 staining, whereas the SCI group exhibited a larger GFAP-positive area than both the normal and the sham groups. The Shh pathway may provide new insights into therapeutic indications and regenerative recovery tools for the treatment of SCI. Activation of the Hh signaling pathway by silencing PTC1 and PTC2 may reduce inflammation and may ultimately promote SCI recovery.


Subject(s)
Genetic Therapy , Inflammation/genetics , Patched-1 Receptor/genetics , Patched-2 Receptor/genetics , Spinal Cord Injuries/genetics , Animals , Disease Models, Animal , Gene Expression Regulation/genetics , Genetic Vectors/administration & dosage , Genetic Vectors/genetics , Hedgehog Proteins/genetics , Humans , Inflammation/pathology , Inflammation/therapy , Lentivirus/genetics , Nestin/genetics , Patched-1 Receptor/antagonists & inhibitors , Patched-2 Receptor/antagonists & inhibitors , Rats , Regeneration/genetics , Signal Transduction/genetics , Smoothened Receptor/genetics , Spinal Cord/pathology , Spinal Cord Injuries/pathology , Spinal Cord Injuries/therapy , Zinc Finger Protein GLI1/genetics
5.
Exp Cell Res ; 355(1): 9-17, 2017 06 01.
Article in English | MEDLINE | ID: mdl-28365245

ABSTRACT

Aberrant activations of Hedegehog (Hh) signaling were found in hepatocellular carcinoma (HCC) and some other cancer types. However, the details have not been completely understood and the underlying mechanism remains unclear. Here we reported that miR-1249 transcription in HCC cells was regulated through direct binding to the conserved sequences in miR-1249 promoter region by Gli1, which functions as a transcription factor and is a component in the Hh signaling pathway. Interestingly, expression of tumor suppressor PTCH1, which is another component of the Hh signaling pathway, was inhibited by miR-1249 through targeting its 3'-untranslated region. Down-regulation of PTCH1 further enhanced the downstream effects mediated by Gli1. In consistent with these findings, miR-1249 expression level was correlated with degree of prognosis (p=0.005) in HCC patients. Taken together, our results suggested the existence of a positive feedback loop comprised of Gli1, miR-1249 and PTCH1. During the process of HCC progression, this positive feedback loop could be continuously activated to enhance tumor cell growth, migration and invasion.


Subject(s)
Carcinoma, Hepatocellular/genetics , Gene Expression Regulation, Neoplastic/genetics , Liver Neoplasms/genetics , MicroRNAs/genetics , Signal Transduction/genetics , Carcinoma, Hepatocellular/metabolism , Down-Regulation/drug effects , Down-Regulation/genetics , Gene Expression Profiling , Humans , Liver Neoplasms/metabolism , MicroRNAs/metabolism , MicroRNAs/pharmacology , Patched-1 Receptor/antagonists & inhibitors , Patched-1 Receptor/genetics , Patched-1 Receptor/metabolism , Tumor Cells, Cultured
6.
Actas Dermosifiliogr ; 107(9): 740-750, 2016 Nov.
Article in English, Spanish | MEDLINE | ID: mdl-27436804

ABSTRACT

A wide range of treatments is now available for nonmelanoma skin cancer, including 5-fluorouracil, ingenol mebutate, imiquimod, diclofenac, photodynamic therapy, methotrexate, cetuximab, vismodegib, and radiotherapy. All are associated with high clinical and histologic response rates. However, some tumors do not respond due to resistance, which may be primary or acquired. Study of the resistance processes is a broad area of research that aims to increase our understanding of the nature of each tumor and the biologic features that make it resistant, as well as to facilitate the design of new therapies directed against these tumors. In this second article, having covered the topical treatments of nonmelanoma skin cancer, we review resistance to other nonsurgical treatments, such as monoclonal antibodies against basal and squamous cell carcinomas, intralesional chemotherapy, photodynamic therapy, and radiotherapy.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma/drug therapy , Drug Resistance, Neoplasm , Photochemotherapy , Skin Neoplasms/drug therapy , Anilides/administration & dosage , Anilides/pharmacology , Anilides/therapeutic use , Antigen-Presenting Cells/drug effects , Antimetabolites, Antineoplastic/administration & dosage , Antimetabolites, Antineoplastic/pharmacology , Antimetabolites, Antineoplastic/therapeutic use , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacology , Carcinoma/genetics , Carcinoma/radiotherapy , Cetuximab/administration & dosage , Cetuximab/pharmacology , Cetuximab/therapeutic use , Clinical Trials as Topic , Combined Modality Therapy , Drug Resistance, Neoplasm/physiology , ErbB Receptors/antagonists & inhibitors , Humans , Injections, Intralesional , Keratoacanthoma/drug therapy , Meta-Analysis as Topic , Methotrexate/administration & dosage , Methotrexate/pharmacology , Methotrexate/therapeutic use , Neoplasm Proteins/antagonists & inhibitors , Neoplasm Proteins/physiology , Neoplastic Stem Cells/drug effects , Patched-1 Receptor/antagonists & inhibitors , Photosensitizing Agents/administration & dosage , Photosensitizing Agents/pharmacology , Photosensitizing Agents/therapeutic use , Pyridines/administration & dosage , Pyridines/pharmacology , Pyridines/therapeutic use , Radiation Tolerance/genetics , Radiation Tolerance/physiology , Skin Neoplasms/genetics , Skin Neoplasms/radiotherapy
SELECTION OF CITATIONS
SEARCH DETAIL
...